Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy.

By L. Hofmann, A. Forschner, C. Loquai, S. Goldinger, L. Zimmer, Selma Ugurel, M. Schmidgen, R. Gutzmer, J. Utikal, D. Göppner and 18 more. European Journal of Cancer, 2016

626 citations recorded by the source corpus.

Subfields: Epidemiology, Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/4508411ba2de09d15c08260a5667f10a206ad1e9

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. C. Robert

In Oncology

1. C. Robert
2. J. Haanen
3. J. Larkin
4. K. Kerr
5. S. Peters
6. F. Carbonnel

Citations in the corpus

• Myocarditis in Patients Treated With Immune Checkpoint Inhibitors (2018, neutral): “hepatitis with anti-PD1 and anti-CTLA4 as single agents or in combination (0% to 18% grade 4, no grade 5) (26–28), and severe diarrhea or colitis with anti-PD1 (0% grade 4 or 5) (28).”
• Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2017, background): “Renal dysfunction is rare with ipilimumab and with anti-PD-1 therapies, occurring in <1% of treated patients [77].”
• Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018, background): “Renal dysfunction is rare with ipilimumab and with anti-PD-1 therapies, occurring in <1% of treated patients [78].”